Loading...
ROCO
6662
Market cap23mUSD
Jul 09, Last price  
29.40TWD
1D
-1.01%
1Q
-4.23%
IPO
-55.05%
Name

BioLASCO Taiwan Co Ltd

Chart & Performance

D1W1MN
ROCO:6662 chart
P/E
P/S
EPS
1.66
Div Yield, %
5.10%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
-2.55%
Revenues
263m
-10.20%
346,686,000298,879,000227,580,000235,912,000264,723,000292,498,000262,664,000
Net income
42m
-3.63%
54,973,00062,802,00045,153,00042,311,00049,743,00044,028,00042,428,000
CFO
49m
-14.33%
128,293,00073,535,00070,842,00044,689,00029,459,00056,861,00048,710,000
Dividend
Aug 07, 20251.5 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BioLASCO Taiwan Co., Ltd., established in Taipei in 1990, operates as an international supplier of bio-materials and surgical support services. The company specializes in breeding and producing Specific Pathogen-Free (SPF) laboratory rodents, encompassing various outbreed stocks, inbreed strains, and immune-deficient models, alongside providing bespoke animal model services. Its product portfolio extends to critical diagnostic and research tools, including kits for endotoxin detection, animal health diagnostics, and serological analysis, as well as biological indicators. Furthermore, BioLASCO furnishes a comprehensive array of laboratory equipment vital for animal research and facility management. This sophisticated equipment includes Individually Ventilated Cage (IVC) systems and ventilated housing units, professional automated animal watering systems, transponders, chlorine dioxide gas generators, and specialized devices such as mouse and rat tail cuff blood pressure systems, analgesia equipment, animal behavioral systems, metabolism and behavior tracking systems. The company also offers XPERT cabinet X-ray systems, automatic cleaning equipment, laboratory workstations, isolation chambers, and foggers.
IPO date
Jan 04, 2018
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT